<DOC>
	<DOCNO>NCT00152126</DOCNO>
	<brief_summary>Studies provide evidence residual microscopic malignant cell autologous bone marrow blood stem cell graft contribute posttransplant relapse . Researchers currently explore different method attempt purify `` purge '' stem cell product minimize risk tumor contamination . The CD133+ antigen protein contain `` express '' numerous cell human body include specific hematopoietic progenitor ( blood forming ) cell . However , antigen express certain cancer cell include neuroblastoma . A technique use investigational CliniMACS cell sort device develop effort filter stem cell express CD133+ antigen order infuse hematopoietic stem cell product tumor contamination potential . The primary objective study establish safety treat patient high dose chemotherapy regimen Busulfan Melphalan follow autologous CD133+ hematopoietic stem cell support . Transplants recipient expect achieve engraftment define absolute neutrophil count great equal 500/mm3 three consecutive day day 42-post infusion . Thus , safety treatment plan evaluate term failure engraft specific time period .</brief_summary>
	<brief_title>Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells Children With Solid Tumors Lymphomas</brief_title>
	<detailed_description>Secondary objective protocol include follow : - To describe CD133+ graft content post-selection describe yield purity CD133+ content graft obtain . - To describe negative selection efficiency strategy assess process product tumor specific marker , applicable . - To characterize proliferation clonal progeny CD133+ cell . - To characterize lymphocyte hematopoietic reconstitution ( include kinetics platelet engraftment ) patient . - To estimate one-year disease-free overall survival transplant recipient .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Eligibility determine separately Part I Part II study : Part I ( Part I Eligibility criterion ( eligibility undergo apheresis procedure ) Age ≤ 25 year initial diagnosis . Must one follow diagnosis : High risk neuroblastoma Metastatic recurrent retinoblastoma High risk rain tumor Recurrent refractory Hodgkin disease Recurrent advance stage Wilms tumor Recurrent metastatic sarcoma Recurrent refractory nonHodgkin lymphoma Desmoplastic small round cell tumor . Lansky Karnofsky Performance Score ≥ 70 . Creatinine ≤ 2.0 mg/dl . Direct bilirubin ≤ 2.0 mg/dl . SGPT ≤ 2 x upper limit normal HIV test Negative pregnancy test Patients significant prior radiation therapy liver exclude . Part II eligibility criterion ( criterion transplantation CD133 select stem cell product ) Successfully complete Part I protocol treatment plan follow available : Stored autologous bone marrow peripheral blood stem cell ( i.e . 2 x 106 unselected CD34+ cells/ kg PBSC 1 x 106 CD34+ cells/ kg BM ) back . Stored autologous bone marrow peripheral blood stem cell ( 2 x 106 CD133+ cells/ kg PBSC 2 x 106 CD133+ cells/ kg BM ) infusion . Forced vital capacity great equal 40 % normal pulse oximetry great equal 92 % room air . Lansky Karnofsky Performance Score ≥ 70 . Creatinine ≤ 2.0 mg/dl . Direct bilirubin ≤ 2.0 mg/dl . SGPT ≤ 2 x upper limit normal Negative pregnancy test Patients significant prior radiation therapy ( opinion PI ) liver exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Autologous stem cell transplantation</keyword>
	<keyword>CD133 cell selection</keyword>
	<keyword>CliniMACS device</keyword>
	<keyword>Tumor marker</keyword>
	<keyword>Tumor purging</keyword>
</DOC>